EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Acarbose impairs gut Bacteroides growth by targeting intracellular glucosidases

Haley A Brown iD, Adeline L Morris, Nicholas A Pudlo, Ashley E Hopkins, Eric C Martens iD, Jonathan L Golob iD, Nicole M Koropatkin iD

mBio · 2024

DOI: 10.1128/mbio.01506-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Haley A Brown und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Acarbose, Bacteroides, Bacteroides thetaiotaomicron, Starch. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | National Institutes of Health (NIH), NIDDK NIH HHS, University of Michigan (U-M).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acarbose is a type 2 diabetes medicine that prevents dietary starch breakdown into glucose by inhibiting host amylase and glucosidase enzymes. Numerous gut species in the Bacteroides genus enzymatically break down starch and change in relative abundance within the gut microbiome in acarbose-treated individuals. To mechanistically explain this observation, we used two model starch-degrading Bacteroides , Bacteroides ovatus (Bo), and Bacteroides thetaiotaomicron (Bt). Bt growth on starch polysaccharides is severely impaired by acarbose, whereas Bo growth is much less affected by the drug. The Bacteroides use a starch utilization system (Sus) to grow on starch. We hypothesized that Bo and Bt Sus enzymes are differentially inhibited by acarbose. Instead, we discovered that although acarbose primarily targets the Sus periplasmic GH97 enzymes in both organisms, the drug affects starch processing at multiple other points. Acarbose competes for transport through the TonB-dependent SusC proteins and binds to the Sus transcriptional regulators. Furthermore, Bo expresses a non-Sus GH97 (BoGH97D) when grown in starch with acarbose. The Bt homolog, BtGH97H, is not expressed in the same conditions, nor can overexpression of BoGH97D complement the Bt growth inhibition in the presence of acarbose. This work informs us about unexpected complexities of Sus function and regulation in Bacteroides , including variation between related species. Furthermore, this indicates that the gut microbiome may be a source of variable response to acarbose treatment for diabetes. IMPORTANCE Acarbose is a type 2 diabetes medication that works primarily by stopping starch breakdown into glucose in the small intestine. This is accomplished by the inhibition of host enzymes, leading to better blood sugar control via reduced ability to derive glucose from dietary starches. The drug and undigested starch travel to the large intestine where acarbose interferes with the ability of some bacteria to grow on starch. However, little is known about how gut bacteria interact with acarbose, including microbes that can use starch as a carbon source. Here, we show that two gut species, Bacteroides ovatus (Bo) and Bacteroides thetaiotaomicron (Bt), respond differently to acarbose: Bt growth is inhibited by acarbose, while Bo growth is less affected. We reveal a complex set of mechanisms involving differences in starch import and sensing behind the different Bo and Bt responses. This indicates the gut microbiome may be a source of variable response to acarbose treatment for diabetes via complex mechanisms in common gut microbes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcarboseBacteroidesBacteroides thetaiotaomicronStarchGastrointestinal MicrobiomeGlucosidasesHumansBacterial Proteins

Stichwörter der Autor:innen

Bacteroidotaacarbosealpha-amylaseglucosidaseglycoside hydrolase family 13glycoside hydrolase family 97

Substanzen

AcarboseStarchGlucosidasesBacterial Proteins

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA.

ORCID-Profile: Haley A Brown, Eric C Martens, Jonathan L Golob, Nicole M Koropatkin

Förderung

  • HHS | National Institutes of Health (NIH)
  • NIDDK NIH HHS
  • University of Michigan (U-M)
  • NCCIH NIH HHS
  • NIGMS NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Brown, H. A., Morris, A. L., Pudlo, N. A., Hopkins, A. E., Martens, E. C., Golob, J. L., & Koropatkin, N. M. (2024). Acarbose impairs gut Bacteroides growth by targeting intracellular glucosidases. mBio. https://doi.org/10.1128/mbio.01506-24

Vancouver

Brown HA, Morris AL, Pudlo NA, Hopkins AE, Martens EC, Golob JL, et al. Acarbose impairs gut Bacteroides growth by targeting intracellular glucosidases. mBio. 2024. doi:10.1128/mbio.01506-24

BibTeX
@article{Brown2024,
  author = {Brown, Haley A and Morris, Adeline L and Pudlo, Nicholas A and Hopkins, Ashley E and Martens, Eric C and Golob, Jonathan L and Koropatkin, Nicole M},
  title = {Acarbose impairs gut Bacteroides growth by targeting intracellular glucosidases},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.01506-24}
}
Kostenlos starten →